331 related articles for article (PubMed ID: 19465073)
21. Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA.
Sakurai Y; Hatakeyama H; Sato Y; Akita H; Takayama K; Kobayashi S; Futaki S; Harashima H
Biomaterials; 2011 Aug; 32(24):5733-42. PubMed ID: 21605898
[TBL] [Abstract][Full Text] [Related]
22. A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo.
Sato Y; Hatakeyama H; Sakurai Y; Hyodo M; Akita H; Harashima H
J Control Release; 2012 Nov; 163(3):267-76. PubMed ID: 23000694
[TBL] [Abstract][Full Text] [Related]
23. Octaarginine- and octalysine-modified nanoparticles have different modes of endosomal escape.
El-Sayed A; Khalil IA; Kogure K; Futaki S; Harashima H
J Biol Chem; 2008 Aug; 283(34):23450-61. PubMed ID: 18550548
[TBL] [Abstract][Full Text] [Related]
24. Multifunctional envelope-type nano device (MEND) as a non-viral gene delivery system.
Kogure K; Akita H; Yamada Y; Harashima H
Adv Drug Deliv Rev; 2008 Mar; 60(4-5):559-71. PubMed ID: 18037529
[TBL] [Abstract][Full Text] [Related]
25. Construction of a multifunctional envelope-type nano device by a SUV*-fusion method.
Sasaki K; Kogure K; Chaki S; Kihira Y; Ueno M; Harashima H
Int J Pharm; 2005 May; 296(1-2):142-50. PubMed ID: 15885466
[TBL] [Abstract][Full Text] [Related]
26. Efficient short interference RNA delivery to tumor cells using a combination of octaarginine, GALA and tumor-specific, cleavable polyethylene glycol system.
Sakurai Y; Hatakeyama H; Akita H; Oishi M; Nagasaki Y; Futaki S; Harashima H
Biol Pharm Bull; 2009 May; 32(5):928-32. PubMed ID: 19420766
[TBL] [Abstract][Full Text] [Related]
27. Development of lipid particles targeted via sugar-lipid conjugates as novel nuclear gene delivery system.
Masuda T; Akita H; Nishio T; Niikura K; Kogure K; Ijiro K; Harashima H
Biomaterials; 2008 Feb; 29(6):709-23. PubMed ID: 18001828
[TBL] [Abstract][Full Text] [Related]
28. A DNA microarray-based analysis of immune-stimulatory and transcriptional responses of dendritic cells to KALA-modified nanoparticles.
Akita H; Ishii S; Miura N; Shaheen SM; Hayashi Y; Nakamura T; Kaji N; Baba Y; Harashima H
Biomaterials; 2013 Nov; 34(35):8979-90. PubMed ID: 23968857
[TBL] [Abstract][Full Text] [Related]
29. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid.
Hatakeyama H; Akita H; Kogure K; Oishi M; Nagasaki Y; Kihira Y; Ueno M; Kobayashi H; Kikuchi H; Harashima H
Gene Ther; 2007 Jan; 14(1):68-77. PubMed ID: 16915290
[TBL] [Abstract][Full Text] [Related]
30. Application of an HIV gp41-derived peptide for enhanced intracellular trafficking of synthetic gene and siRNA delivery vehicles.
Kwon EJ; Bergen JM; Pun SH
Bioconjug Chem; 2008 Apr; 19(4):920-7. PubMed ID: 18376855
[TBL] [Abstract][Full Text] [Related]
31. Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid.
Hatakeyama H; Akita H; Ito E; Hayashi Y; Oishi M; Nagasaki Y; Danev R; Nagayama K; Kaji N; Kikuchi H; Baba Y; Harashima H
Biomaterials; 2011 Jun; 32(18):4306-16. PubMed ID: 21429576
[TBL] [Abstract][Full Text] [Related]
32. Significant and prolonged antisense effect of a multifunctional envelope-type nano device encapsulating antisense oligodeoxynucleotide.
Nakamura Y; Kogure K; Yamada Y; Futaki S; Harashima H
J Pharm Pharmacol; 2006 Apr; 58(4):431-7. PubMed ID: 16597360
[TBL] [Abstract][Full Text] [Related]
33. Improving in vivo hepatic transfection activity by controlling intracellular trafficking: the function of GALA and maltotriose.
Akita H; Masuda T; Nishio T; Niikura K; Ijiro K; Harashima H
Mol Pharm; 2011 Aug; 8(4):1436-42. PubMed ID: 21598999
[TBL] [Abstract][Full Text] [Related]
34. Non-linear pharmacodynamics in a non-viral gene delivery system: positive non-linear relationship between dose and transfection efficiency.
Moriguchi R; Kogure K; Iwasa A; Akita H; Harashima H
J Control Release; 2006 Feb; 110(3):605-9. PubMed ID: 16360229
[TBL] [Abstract][Full Text] [Related]
35. The role of dioleoylphosphatidylethanolamine (DOPE) in targeted gene delivery with mannosylated cationic liposomes via intravenous route.
Hattori Y; Suzuki S; Kawakami S; Yamashita F; Hashida M
J Control Release; 2005 Nov; 108(2-3):484-95. PubMed ID: 16181701
[TBL] [Abstract][Full Text] [Related]
36. Comparison between a multifunctional envelope-type nano device and lipoplex for delivery to the liver.
Yamauchi J; Hayashi Y; Kajimoto K; Akita H; Harashima H
Biol Pharm Bull; 2010; 33(5):926-9. PubMed ID: 20460780
[TBL] [Abstract][Full Text] [Related]
37. Efficient and High-Speed Transduction of an Antibody into Living Cells Using a Multifunctional Nanocarrier System to Control Intracellular Trafficking.
Yamada Y; Perez SM; Tabata M; Abe J; Yasuzaki Y; Harashima H
J Pharm Sci; 2015 Sep; 104(9):2845-54. PubMed ID: 25546552
[TBL] [Abstract][Full Text] [Related]
38. [Development of various multifunctional envelope-type nano device MEND based on novel assembly technologies].
Kogure K; Akita H; Harashima H
Yakugaku Zasshi; 2008 Feb; 128(2):219-32. PubMed ID: 18239369
[TBL] [Abstract][Full Text] [Related]
39. The transfection activity of R8-modified nanoparticles and siRNA condensation using pH sensitive stearylated-octahistidine.
Toriyabe N; Hayashi Y; Harashima H
Biomaterials; 2013 Jan; 34(4):1337-43. PubMed ID: 23141897
[TBL] [Abstract][Full Text] [Related]
40. Multifunctional envelope-type nano device for non-viral gene delivery: concept and application of Programmed Packaging.
Kogure K; Akita H; Harashima H
J Control Release; 2007 Oct; 122(3):246-51. PubMed ID: 17651856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
